The OHSU Knight Cancer Institute (Knight) is a matrix cancer center at the Oregon Health &Science University (OHSU) in Portland, Oregon. Founded in 1992 by Grover C. Bagby, Jr. M.D., the Knight has been broadly supported by the university administrative leaders, who have provided space and resources at steadily increasing levels. The Knight Cancer Institute has been supported by the NCI Cancer Center Support Grant since 1997. The OHSU Knight Cancer Institute has 151 members who belong to four scientific programs (Cancer Biology, Hematologic Malignancies, Solid Tumors, and Cancer Prevention and Control). Knight members utilize eight well-established shared resources to perform outstanding research, convert research findings into treatments and preventive agents, and design clinical trials to validate molecular targets. The new Director, Brian Druker, M.D. has sought to refocus the direction of the Knight onto the core values of changing cancer medicine. Institutional investments have added more than 200,000 sq ft in research and clinical space. Sixty-two new members have been added to the Knight, including significant changes in the senior leadership. A gift of $100 million from Phil and Penny Knight (to be given in installments over five to seven years) led to renaming the OHSU Cancer Institute to the OHSU Knight Cancer Institute. Our goal is to invest in people and programs that will advance our mission to make personalized cancer therapy and prevention a reality. As the recognized leader in personalized cancer therapies, our focus has been and will continue to be on investing to make personalized cancer therapy a reality. Investments in people and programs will help us achieve the following goals: 1.) Develop the methodology and capacity to rapidly and comprehensively interrogate individual patient tumors, 2.) Develop the capacity to organize the molecular data into interpretable, pathway focused information, 3.) Develop strategies to understand which pathway alterations are important, 4.) Develop a library of approved and investigational agents that are available to us for human use, 5.) Develop the capacity to rapidly test combinations of therapies targeting multiple genetic abnormalities in cancers, 6.) Develop novel clinical trial designs that will accommodate multi-agent therapies, 7.) Initiate innovative, multi-pathway phase I clinical trials to test our strategy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA069533-15S1
Application #
8530482
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1998-06-22
Project End
2016-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
15
Fiscal Year
2012
Total Cost
$75,000
Indirect Cost
$18,182
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Farrell, Amy S; Joly, Meghan Morrison; Allen-Petersen, Brittany L et al. (2017) MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nat Commun 8:1728
De Maria, Alicia; Wilmarth, Phillip A; David, Larry L et al. (2017) Proteomic Analysis of the Bovine and Human Ciliary Zonule. Invest Ophthalmol Vis Sci 58:573-585
Danelishvili, Lia; Chinison, Jessica J J; Pham, Tuan et al. (2017) The Voltage-Dependent Anion Channels (VDAC) of Mycobacterium avium phagosome are associated with bacterial survival and lipid export in macrophages. Sci Rep 7:7007
Avenarius, Matthew R; Krey, Jocelyn F; Dumont, Rachel A et al. (2017) Heterodimeric capping protein is required for stereocilia length and width regulation. J Cell Biol 216:3861-3881
Cassidy, Pamela B; Liu, Tong; Florell, Scott R et al. (2017) A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Cancer Prev Res (Phila) 10:36-44
Tsujikawa, Takahiro; Kumar, Sushil; Borkar, Rohan N et al. (2017) Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. Cell Rep 19:203-217
Kwon, Sunjong; Chin, Koei; Nederlof, Michel et al. (2017) Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution. Sci Rep 7:16459
Midgett, Madeline; López, Claudia S; David, Larry et al. (2017) Increased Hemodynamic Load in Early Embryonic Stages Alters Endocardial to Mesenchymal Transition. Front Physiol 8:56
Krey, J F; Wilmarth, P A; David, L L et al. (2017) Analysis of the Proteome of Hair-Cell Stereocilia by Mass Spectrometry. Methods Enzymol 585:329-354
Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134

Showing the most recent 10 out of 248 publications